Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06548672 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess the Safety, Pharmacokinetics, and Antitumor Activity of BC3195 in Patients With Advanced or Metastatic Cancer
A Phase 1 study of Advanced Cancer and Metastatic Solid Tumor, sponsored by Biocity Biopharmaceutics Co..
- Recruiting
- Registry status
- Phase 1
- Development phase
- 148
- Enrollment target
- 1
- Study location
NCT06548672 is a Phase 1 study of Advanced Cancer and Metastatic Solid Tumor that is actively recruiting participants, run by Biocity Biopharmaceutics Co.. The registered enrollment target is 148 participants, below the 245-participant average among 122 other Advanced Cancer trials with a reported enrollment target (40% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06548672, a Phase 1 study of Advanced Cancer and Metastatic Solid Tumor, is actively recruiting participants, sponsored by Biocity Biopharmaceutics Co..
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 148 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a phase Ia/Ib, open-label, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of BC3195 in subjects with locally advanced or metastatic solid tumors in whom standard treatment has failed (either due to disease progression or intolerance). This study will consist of two parts: Dose escalation (Part 1) and dose expansion (Part 2). Each part will include a screening period, a treatment period, and follow-up period.
Conditions Studied
Interventions
- DRUG BC3195
Study Locations (1)
Ohio
- Case Western Reserve University - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 148 participants |
| Start Date | 2024-06-24 |
| Est. Completion | 2027-06-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06548672
The ClinicalTrials.gov registry entry for NCT06548672 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 148 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 245-participant average among 122 other Advanced Cancer trials with a reported enrollment target (40% lower). The listed sponsor is Biocity Biopharmaceutics Co., which has 1 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Advanced Cancer appearing as the primary indexed condition, and to 1 intervention - of which BC3195 is the first listed.
NCT06548672 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.
Frequently Asked Questions
What is clinical trial NCT06548672 about?
NCT06548672 is a clinical study titled "A Study to Assess the Safety, Pharmacokinetics, and Antitumor Activity of BC3195 in Patients With Advanced or Metastatic Cancer". This is a phase Ia/Ib, open-label, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of BC3195 in subjects with locally advanced or metastatic solid tumors in whom standard treatment has failed (either due to disease progression o...
What is the current status of trial NCT06548672?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 148 participants. The study started on 2024-06-24. Estimated completion is 2027-06-30.
What conditions does trial NCT06548672 study?
This clinical trial studies the following conditions: Advanced Cancer, Metastatic Solid Tumor.
What interventions are being tested in trial NCT06548672?
The interventions under investigation include: BC3195 (DRUG).
Who is sponsoring clinical trial NCT06548672?
This trial is sponsored by Biocity Biopharmaceutics Co., which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06548672 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase 1b Trial of BMS-986504 in Combination With Olaparib in Patients With MTAP Loss
RECRUITING · Phase 1
-
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Antitumor Activity of ALK202 in Participants with Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study in Patients With Advanced Cancers
RECRUITING · Phase 1
-
A Study of MGC026 in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.